Management of small bowel neuroendocrine tumours
Research type
Research Study
Full title
Management of small bowel neuroendocrine tumours: 10-years’ experience at a specialist tertiary referral centre
IRAS ID
325117
Contact name
Andrea Frilling
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
0 years, 1 months, 1 days
Research summary
Neuroendocrine tumours (NET) of the small bowel (SB) are difficult to treat. They are becoming more common, tumours can be multiple in up to half of cases, and many patients are diagnosed when their tumours are advanced. These tumours often spread to the liver (metastatic).
Therefore, treating people with small bowel neuroendocrine tumours can be complex, with a strong focus on attaining disease control, and aiming for effective treatment of metastatic disease.
Recent advances in the treatment of advanced Small bowel NET include medical therapies (new medications, or targeted types of radiotherapy), but there is increasing interest in combining different types of treatment so that they are more effective.
However there are no trials that look into this.
This study plans to review the experience of a large, specialist centre (Imperial College Healthcare NHS Trust) treating people with small bowel neuroendocrine tumours, explore what the outcomes have been with different types of therapy, and assess the effects of combined (so called 'multimodal' therapy).REC name
East Midlands - Derby Research Ethics Committee
REC reference
23/EM/0102
Date of REC Opinion
24 Apr 2023
REC opinion
Favourable Opinion